Mareike Ostertag has extensive experience in the pharmaceutical industry. In over 16 years with Novartis, Dr. Ostertag held different roles with increasing responsibility within the company as well as with external industry- and non-industry partners.
Roles included Technical Marketing, Global Project Management R&D, Alliance Management R&D as well as Public Private Partnership and Stakeholder Management for Middle East and Africa.
As part of her previous roles, she successfully led Due Diligence projects and was responsible for the integration and Alliance Management of licensed projects into the Novartis portfolio.
In her current role, Mareike Ostertag focusses on policy issues related to R&D across the Novartis Divisions, with specific focus on Orphan Diseases, Biotherapeutics including Biosimilars, IP and R&D incentives.
Dr. Ostertag holds a degree in Veterinary Medicine from the University of Giessen, Germany and a PhD in cellular immunology.
A native German, Mareike Ostertag has been living and working in Switzerland and the US for the past 12 years. She is married and lives outside of Basel, Switzerland today.
Publication: Saunders (now Ostertag), M.; Taubert, A; Dafa’alla, T; Zahner, H:
Effect of chemotherapeutic treatment on cytokine (IFN-γ, IL-2, IL-4, IL-5, IL-10) gene transcription in response to specific antigens in Brugia malayi-infected Mastomys coucha. Parasitol. Res. (2008) 103:1163-1176